Table 2.
Baseline patient characteristics stratified by inflammatory marker levels in grade III glioma.
| Variables | Complete dataset | 1:1 matched dataset | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (n=43) | % | SIRI ≤1.26 (n=25, 58.1% | SIRI >1.26 (n=18, 41.9%) | p | Total (n=30) | % | SIRI ≤1.26 (n=15, 50.0%) | SIRI >1.26 (n=15, 50.0%) | p | |
| N/ M ± SD | N/ M ± SD | N/ M ± SD | N/ M ± SD | N/ M ± SD | N/ M ± SD | |||||
| Age | 48.56 ± 11.189 | 48.40 ± 10.388 | 48.78 ± 12.526 | 0.915 | 47.36 ± 10.393 | 46.43 ± 7.623 | 48.29 ± 12.821 | 0.645 | ||
| Sex | ||||||||||
| female | 16 | 37.2% | 10 | 6 | 0.655 | 12 | 42.9% | 6 | 6 | 1.000 |
| male | 27 | 62.8% | 15 | 12 | 16 | 57.1% | 8 | 8 | ||
| Histology | ||||||||||
| AA | 23 | 53.5% | 15 | 8 | 0.598 | 16 | 57.1% | 8 | 8 | 1.000 |
| AO | 18 | 41.9% | 9 | 9 | 12 | 42.9% | 6 | 6 | ||
| NOS | 2 | 4.7% | 1 | 1 | 0 | 0.0% | 0 | 0 | ||
| Main location | ||||||||||
| frontal | 30 | 69.8% | 19 | 11 | 0.294 | 19 | 67.9% | 10 | 9 | 1.000 |
| parietal | 5 | 11.6% | 3 | 2 | 1.000 | 3 | 10.7% | 2 | 1 | 1.000 |
| occipital | 3 | 7.0% | 2 | 1 | 1.000 | 2 | 7.1% | 1 | 1 | 1.000 |
| temporal | 13 | 30.2% | 6 | 7 | 0.294 | 8 | 28.6% | 3 | 5 | 0.678 |
| insular | 3 | 7.0% | 2 | 1 | 1.000 | 2 | 7.1% | 1 | 1 | 1.000 |
| other | 5 | 11.6% | 2 | 3 | 0.634 | 4 | 14.3% | 1 | 3 | 0.596 |
| No. of glioma | ||||||||||
| single | 41 | 95.3% | 24 | 17 | 1.000 | 27 | 96.4% | 14 | 13 | 1.000 |
| multiple | 2 | 4.7% | 1 | 1 | 1 | 3.6% | 0 | 1 | ||
| Extent of resection | ||||||||||
| PR | 3 | 7.0% | 1 | 2 | 0.567 | 2 | 7.1% | 0 | 2 | 0.162 |
| STR | 4 | 9.3% | 3 | 1 | 3 | 10.7% | 2 | 1 | ||
| NTR | 5 | 11.6% | 4 | 1 | 3 | 10.7% | 3 | 0 | ||
| GTR | 31 | 72.1% | 17 | 14 | 20 | 71.4% | 9 | 11 | ||
| IDH mutation | ||||||||||
| no | 5 | 11.6% | 4 | 1 | 0.380 | 2 | 7.1% | 1 | 1 | 1.000 |
| yes | 38 | 88.4% | 21 | 17 | 26 | 92.9% | 13 | 13 | ||
| MGMT methylation | ||||||||||
| no | 20 | 46.5% | 12 | 8 | 0.818 | 14 | 50.0% | 7 | 7 | 1.000 |
| yes | 23 | 53.5% | 13 | 10 | 14 | 50.0% | 7 | 7 | ||
| 1p19q deletion | ||||||||||
| no | 25 | 58.1% | 16 | 9 | 0.359 | 16 | 57.1% | 8 | 8 | 1.000 |
| yes | 18 | 41.9% | 9 | 9 | 12 | 42.9% | 6 | 6 | ||
| ATRX mutation | ||||||||||
| no | 25 | 58.1% | 13 | 12 | 0.336 | 15 | 53.6% | 7 | 8 | 0.705 |
| yes | 18 | 41.9% | 12 | 6 | 13 | 46.4% | 7 | 6 | ||
| TP53 | ||||||||||
| negative | 7 | 16.3% | 4 | 3 | 1.000 | 3 | 10.7% | 1 | 2 | 1.000 |
| positive | 36 | 83.7% | 21 | 15 | 25 | 89.3% | 13 | 12 | ||
| Ki-67 | 18.02 ± 16.246 | 14.68 ± 13.388 | 22.67 ± 18.967 | 0.113 | 16.11 ± 13.796 | 13.07 ± 11.256 | 19.14 ± 15.772 | 0.252 | ||
| Epilepsy before surgery | ||||||||||
| no | 27 | 62.8% | 15 | 12 | 0.655 | 15 | 53.6% | 6 | 9 | 0.256 |
| yes | 16 | 37.2% | 10 | 6 | 13 | 46.4% | 8 | 5 | ||
AA, anaplastic astrocytomas; AO, anaplastic oligodendrogliomas; GBM, glioblastoma; GTR, gross total resection; M, mean; N, number; NA, not applicable; No., number; NOS, not otherwised speccified; NTR, near total resection; PR, partial resection; SD, standard deviation; SIRI, systemic inflammatory response index; STR, subtotal resection.